Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer

Laura Evangelista; Maria Giuseppina Bonavina; Emilio Bombardieri

doi:10.1016/j.nucmedbio.2017.04.001

Clinical results and economic considerations of ⁶⁸Ga-PSMA and radiolabeled choline in prostate cancer

Laura Evangelista, Maria Giuseppina Bonavina, Emilio Bombardieri

Istituto Oncologico Veneto

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In recent years there was an impressive improvement in the options for the management of patients with prostate cancer. Nuclear Medicine has significantly enriched its diagnostic options, both in radiopharmacy and in instrumentation, in order to accurately target prostatic cancer cells, thus rendering the physicians able to adopt the best therapeutic strategy. In the present analysis, we have evaluated the available published data about 68Ga-PSMA and radio-labeled choline, two radiopharmaceutical agents for positron emission tomography/computed tomography (PET/CT) examination, by reporting clinical information and considering data about legal, economic and organization aspects.

Original language	English
Pages (from-to)	47-49
Number of pages	3
Journal	Nuclear Medicine and Biology
Volume	50
DOIs	https://doi.org/10.1016/j.nucmedbio.2017.04.001
Publication status	Published - Jul 1 2017

Keywords

18F-choline
68Ga-PSMA, 11C-choline
Costs
Pet/Ct
Prostate cancer

ASJC Scopus subject areas

Molecular Medicine
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1016/j.nucmedbio.2017.04.001

Cite this

@article{e560639947284b1cbbd6216d4207e7c1,

title = "Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer",

abstract = "In recent years there was an impressive improvement in the options for the management of patients with prostate cancer. Nuclear Medicine has significantly enriched its diagnostic options, both in radiopharmacy and in instrumentation, in order to accurately target prostatic cancer cells, thus rendering the physicians able to adopt the best therapeutic strategy. In the present analysis, we have evaluated the available published data about 68Ga-PSMA and radio-labeled choline, two radiopharmaceutical agents for positron emission tomography/computed tomography (PET/CT) examination, by reporting clinical information and considering data about legal, economic and organization aspects.",

keywords = "18F-choline, 68Ga-PSMA, 11C-choline, Costs, Pet/Ct, Prostate cancer",

author = "Laura Evangelista and Bonavina, {Maria Giuseppina} and Emilio Bombardieri",

year = "2017",

month = jul,

day = "1",

doi = "10.1016/j.nucmedbio.2017.04.001",

language = "English",

volume = "50",

pages = "47--49",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer

AU - Evangelista, Laura

AU - Bonavina, Maria Giuseppina

AU - Bombardieri, Emilio

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In recent years there was an impressive improvement in the options for the management of patients with prostate cancer. Nuclear Medicine has significantly enriched its diagnostic options, both in radiopharmacy and in instrumentation, in order to accurately target prostatic cancer cells, thus rendering the physicians able to adopt the best therapeutic strategy. In the present analysis, we have evaluated the available published data about 68Ga-PSMA and radio-labeled choline, two radiopharmaceutical agents for positron emission tomography/computed tomography (PET/CT) examination, by reporting clinical information and considering data about legal, economic and organization aspects.

AB - In recent years there was an impressive improvement in the options for the management of patients with prostate cancer. Nuclear Medicine has significantly enriched its diagnostic options, both in radiopharmacy and in instrumentation, in order to accurately target prostatic cancer cells, thus rendering the physicians able to adopt the best therapeutic strategy. In the present analysis, we have evaluated the available published data about 68Ga-PSMA and radio-labeled choline, two radiopharmaceutical agents for positron emission tomography/computed tomography (PET/CT) examination, by reporting clinical information and considering data about legal, economic and organization aspects.

KW - 18F-choline

KW - 68Ga-PSMA, 11C-choline

KW - Costs

KW - Pet/Ct

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85018630197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018630197&partnerID=8YFLogxK

U2 - 10.1016/j.nucmedbio.2017.04.001

DO - 10.1016/j.nucmedbio.2017.04.001

M3 - Comment/debate

C2 - 28438468

AN - SCOPUS:85018630197

SN - 0969-8051

VL - 50

SP - 47

EP - 49

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

ER -